




Tudor I. Oprea, MD, PhD, is a digital drug hunter active in artificial intelligence and knowledge management for target and drug discovery. Three drugs he co-invented reached clinical trials, including R-ketorolac for ovarian cancer, and LNS8801, a first-in-class orphan drug designated in Phase 2/3 for uveal melanoma. His predictive models cover diseases, targets, and chemicals, with documented validation for novel target-disease associations and bioactive molecules for GPCRs, transporters, and enzymes. He has made significant contributions to disease and chemical biology: systems chemical biology, lead-likeness, temporal disease trajectories, and a knowledge-based classification of human proteins. He co-created DrugCentral and Pharos, two open-source platforms. Oprea is now CEO at Expert Systems Inc. (San Diego, CA) and Professor Emeritus of Medicine at UNM Health Sciences Center (Albuquerque, NM).